Galapagos NV, a Belgium-based, clinical stage biotech company focused on developing novel mode of action medicines, recently announced it has received a €2.5 million grant from the Flemish Agency for Innovation through Science and Technology (IWT), which is meant to fund the company’s further research and development of new antibiotics. Working…
The Welsh Government is set to launch a year-long campaign, called “Time to Talk” that aims to ensure their employees are well-informed of the soon-to-be implemented shift to a soft opt-out system of organ donation, and what choices are available to them. Those who do not register will be considered…
The 26th edition of the Carleton Cup, an annual race dedicated to fundraising for the charitable organization Cystic Fibrosis Canada, is taking place this Saturday, January 24th at the largest skating rink in the world, the Rideau Canal, in Ottawa, Canada. Already dubbed as “The Ultimate Canadian Triathlon,” the event aims to join sports with…
U.S. lawmakers recently introduced new legislation that could greatly benefit thousands of Americans suffering from cystic fibrosis (CF) and other rare diseases with largely unmet clinical needs by helping them gain access to and participate in clinical trials without having to worry about their health…
British parliament is currently debating the plans of England’s National Health Service (NHS) to transfer more healthcare management responsibilities from national specialized services to local commissioners. However, the debate is generating a major discussion in UK healthcare circles about the risks that could come from trusting the specialized care of chronic and…
International outsourcing services provider, CROMSOURCE, which works with pharmaceutical, biotech and medical device companies, is providing a series of training modules on the best practices for clinical research regarding specialized conditions, including cystic fibrosis (CF). The course is being organized by the Italian Cystic Fibrosis Society (SIFC) and is taking place until…
Vertex Pharmaceuticals, Inc., a pharmaceutical company known for discovering, developing and commercializing novel medicines for serious diseases with largely unmet clinical needs such as cystic fibrosis (CF), recently revealed the company’s corporate outlook for the year 2015, prior to their scheduled presentation at the highly-anticipated 33rd J.P. Morgan Healthcare…
Norwood, Massachusetts-based, Corbus Pharmaceuticals Holdings, Inc., recently announced their Chief Executive Officer, Yuval Cohen, Ph.D., has been invited to present at two upcoming investor conferences. Both presentations will highlight and discuss Corbus’ lead pipeline therapeutic for serious inflammatory and fibrotic conditions, Resunab™, which has as its active ingredient, ajulemic…
Protalix BioTherapeutics, Inc., an Israeli pharmaceutical company known for its proprietary, US Food and Drug Administration-approved, plant-based enzyme taliglucerase alfa for Gaucher disease, recently announced their new company strategy for accelerated growth. The Company has begun reinforcing their R&D efforts and laying new groundwork for a renewed focus on…
As the year 2014 comes to a close, Cystic Fibrosis News Today — your reliable online source for the latest on cystic fibrosis treatments, events, clinical trials, and research updates — has outlined our “Top 14 Cystic Fibrosis Stories of 2014.” The following 14 stories were ranked according to the…
Visit the Cystic Fibrosis News Today forums to connect with others in the CF community.
Get regular updates to your inbox.